PRÉCIS
OESOPHAGEAL SQUAMOUS CELL CARCINOMA
In this Phase Ib study, durvalumab and tremelimumab in combination with first‐line chemotherapy demonstrated manageable safety and antitumor activity in patients with advanced or metastatic esophageal squamous cell carcinoma.